Page last updated: 2024-11-12

s-nitrosohomocysteine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

S-nitrosohomocysteine: in contrast to homocysteine, the nitroso cpd does not support hydrogen peroxide generation & does not lead to endothelial dysfunction [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15731147
CHEMBL ID469866
SCHEMBL ID218864
MeSH IDM0212074

Synonyms (7)

Synonym
s-nitrosohomocysteine
CHEMBL469866
139427-42-2
SCHEMBL218864
s-nitroso-l-homocysteine
l-homocysteine, s-nitroso-
AKOS040747488

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" These data indicate that NO ameliorates the potential, adverse properties of HC via S-nitrosylation in the pathogenesis of hyperhomocysteinemia."( S-nitrosation ameliorates homocysteine-induced neurotoxicity and calcium responses in primary culture of rat cortical neurons.
Kim, WK, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID386464Inactivation of human recombinant DDAH1 assessed as inactivation rate at pH 7.52007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia.
AID386457Inhibition of human recombinant DDAH1 assessed as inactivation rate at 0.6 mM2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia.
AID386458Inhibition of human recombinant DDAH1 assessed as inactivation rate at 0.8 mM2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia.
AID386459Inhibition of human recombinant DDAH1 assessed as inactivation rate at 1.5 mM2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia.
AID386455Inhibition of human recombinant DDAH1 assessed as inactivation rate at 0.2 mM2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia.
AID386456Inhibition of human recombinant DDAH1 assessed as inactivation rate at 0.4 mM2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia.
AID386461Inhibition of human recombinant DDAH1 assessed as inactivation rate at 4.0 mM2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia.
AID386460Inhibition of human recombinant DDAH1 assessed as inactivation rate at 2.0 mM2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Inhibition of human dimethylarginine dimethylaminohydrolase-1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (33.33)18.2507
2000's12 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.47 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (21.05%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (78.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]